Hematologia

Perspectiva | Uma vez visto como um tratamento promissor da COVID-19, o plasma convalescente cai em desuso.

10 Mar, 2022 | 15:49h

Once Viewed as a Promising COVID-19 Treatment, Convalescent Plasma Falls Out of Favor – JAMA

---

Segurança e eficácia do de-escalonamento e descontinuação de antibióticos em pacientes hematológicos de alto risco com neutropenia febril: experiência de centro único.

10 Mar, 2022 | 15:17h

Safety and Efficacy of Antibiotic De-escalation and Discontinuation in High-Risk Hematological Patients With Febrile Neutropenia: A Single-Center Experience – Open Forum Infectious Diseases

Conteúdo relacionado: Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology

 

Comentário no Twitter

OFID: In high-risk hematological patients w/ febrile neutropenia, antibiotic de-escalation and discontinuation prior to neutrophil recovery did not lead to an increase in infectious complications. https://t.co/eUer1fmoc6 #IDSAJournals @PaulSaxMD @DrJLi @FungalDoc @jobadd pic.twitter.com/HuGRYA8YW3

— IDSA (@IDSAInfo) January 5, 2022

 

---

Estudo randomizado | Em pacientes com choque hemorrágico relacionado a trauma recebendo cuidados pré-hospitalares, não houve benefício na ressuscitação com hemoderivados em comparação com o cloreto de sódio 0,9%.

9 Mar, 2022 | 13:49h

Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Haematology

Comentário convidado: Prehospital blood transfusion: who benefits? – The Lancet Haematology

 

Comentário no Twitter

NEW research—resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care: results of #RePHILL, a randomised, controlled, phase 3 trial #openaccess #EmergencyMedicine 🚑🩸https://t.co/Ci0lMMCryX pic.twitter.com/iWEtV12N1r

— The Lancet Haematology (@TheLancetHaem) March 8, 2022

 

---

Revisão | Cardiotoxicidade da terapia com antígeno quimérico receptor de célula T para malignidades avançadas.

9 Mar, 2022 | 13:28h

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies – European Heart Journal

---

Revisão sistemática | Anticoagulantes para pessoas internadas com COVID-19.

8 Mar, 2022 | 17:53h

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Resumo: Do blood thinners prevent people who are hospitalised with COVID-19 from developing blood clots? – Cochrane Library

Conteúdo relacionado: Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.

---

M-A | Eficácia das vacinas contra Covid-19 em pacientes imunocomprometidos.

8 Mar, 2022 | 16:16h

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

Comunicado de imprensa: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Conteúdos relacionados: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Comentário no Twitter

NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav

— The BMJ (@bmj_latest) March 3, 2022

 

---

Diretriz | Tratamento da infecção por Clostridioides difficile em receptores de transplante de células hematopoiéticas.

3 Mar, 2022 | 15:47h

American Society for Transplantation and Cellular Therapy Series: #5 – Management of Clostridioides difficile infection in hematopoietic cell transplant recipients – Transplantation and Cellular Therapy

Ver outros artigos da série:

American Society of Transplantation and Cellular Therapy Series, 1: Enterobacterales Infection Prevention and Management after Hematopoietic Cell Transplantation

 

American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients

 

American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation

 

American Society for Transplantation and Cellular Therapy Series: #4 – Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation

---

Revisão JACC | Anticoagulação em pacientes com COVID-19.

2 Mar, 2022 | 11:42h

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Comentário: Review of Anticoagulation in Patients With COVID-19: Key Points – American College of Cardiology

---

Diretrizes clínicas SEOM para profilaxia de doenças infecciosas em pacientes oncológicos.

2 Mar, 2022 | 11:35h

SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients – Clinical and Translational Oncology

---

Dois amplos estudos de base populacional mostram um risco ligeiramente aumentado de eventos trombóticos após vacinação contra COVID-19 com a vacina da AstraZeneca.

24 Fev, 2022 | 15:47h

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England – PLOS Medicine

Ver também: First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales – PLOS Medicine

Comentários:

Two studies find only small elevated risk of blood clots following AstraZeneca COVID-19 vaccination – PLOS

Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD

---